Innovent Biologics (IVBXF) News Today $4.58 -0.22 (-4.58%) (As of 12/20/2024 05:55 PM ET) Add Compare Share Share Headlines Stock AnalysisChartHeadlinesShort Interest All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 Time Period Innovent and Lilly Expand Collaboration Through Agreement on Commercialization Rights for Jaypirca® (pirtobrutinib) in Mainland ChinaDecember 16, 2024 | finance.yahoo.comInnovent Presents Updated Data From Innovative Anti-CLDN18.2 ADC (IBI343) Phase 1 Study in Patients with Advanced Pancreatic Cancer at the ESMO Asia Congress 2024December 8, 2024 | prnewswire.comHUTCHMED Gains Approval for Innovative Cancer TherapyDecember 4, 2024 | msn.comInnovent Biologics Secures New Approval for Cancer TreatmentDecember 4, 2024 | markets.businessinsider.comInnovent Announces First-Time Inclusion of SINTBILO® and New Indication for Olverembatinib in China's National Reimbursement Drug ListNovember 27, 2024 | prnewswire.comInnovent to Present Clinical Data of Multiple Novel Molecules at ESMO Asia 2024November 24, 2024 | prnewswire.comClaudin 18.2 Targeted Therapy Market Forecast & Clinical Trials Insights Report 2024-2029: Innovent, MabWorks, and Biotheus are Making Substantial ProgressNovember 22, 2024 | globenewswire.comInnovent Ditches Low-Value Stake Sale After Investor OutcryNovember 7, 2024 | benzinga.comInnovent Biologics Inc.November 6, 2024 | wsj.comInnovent Biologics: Strong Sales Momentum and Growth Potential Drive Buy RatingNovember 6, 2024 | markets.businessinsider.comJ.P. Morgan Keeps Their Buy Rating on Innovent Biologics (IVBXF)October 31, 2024 | markets.businessinsider.comInnovent Biologics says picankibart phase 2 study met primary endpointOctober 29, 2024 | markets.businessinsider.comInnovent Announces Results of a Phase 2 Study of Picankibart (Anti-IL-23p19 Antibody) in Plaque Psoriasis, Showing Efficacy in Patients with Prior Inadequate Response to IL-17 BiologicsOctober 28, 2024 | prnewswire.comInnovent Biologics Sells Minority Stake in SubsidiaryOctober 25, 2024 | msn.comInnovent’s trial of picankibart for ulcerative colitis meets primary endpointOctober 18, 2024 | msn.comInnovent Announces Phase 2 Clinical Study of Picankibart (IBI112) in Chinese Patients with Ulcerative Colitis Met Primary EndpointOctober 16, 2024 | prnewswire.comInnovent and Ask Pharm Announce Strategic Collaboration for Limertinib, a Third-generation EGFR TKI for the Treatment of Lung CancerOctober 7, 2024 | prnewswire.comInnovent Announces NMPA Acceptance of NDA for Picankibart (Anti-IL-23p19 Antibody) for Treating Moderate to Severe Plaque PsoriasisSeptember 26, 2024 | prnewswire.comInnovent Delivers Oral Presentations on Clinical Data of IBI354 (HER2 Monoclonal Antibody-Camptothecin Derivative Conjugate) in Advanced Ovarian Cancer, Breast Cancer and Other ...September 19, 2024 | msn.comInnovent Delivers Oral Presentations on Clinical Data of IBI354 (HER2 Monoclonal Antibody-Camptothecin Derivative Conjugate) in Advanced Ovarian Cancer, Breast Cancer and Other Solid Tumors at the 2024 ESMO CongressSeptember 17, 2024 | prnewswire.comInnovent Announces Clinical Data of IBI363 (First-in-class PD-1/IL-2α-bias Bispecific Antibody Fusion Protein) Combined with Bevacizumab in Advanced Colorectal Cancer at the 2024 ESMO CongressSeptember 17, 2024 | prnewswire.comHead-to-head Superiority over Dulaglutide: Innovent's Phase 3 Clinical Trial DREAMS-2 of Mazdutide in Chinese Patients with Type 2 Diabetes were Orally Presented at EASD 2024September 11, 2024 | prnewswire.comInnovent Delivers Oral Presentation on Phase 1 Clinical Data of IBI363 (First-in-class PD-1/IL-2α-bias Bispecific Antibody Fusion Protein) in Advanced Non-small Cell Lung Cancer at the 2024 WCLCSeptember 10, 2024 | prnewswire.comInnovent Delivers Oral Presentation of Updated Results from a Pivotal Phase 2 Study of Dupert® (Fulzerasib) in Patients with Advanced Non-Small Cell Lung Cancer Harboring KRAS G12C MutationSeptember 9, 2024 | prnewswire.comInnovent Receives Fast Track Designation from the U.S. FDA for IBI363 (PD-1/IL-2α Bispecific Antibody Fusion Protein) as Monotherapy for Advanced MelanomaSeptember 3, 2024 | prnewswire.comInnovent Annouces Multiple Clinical Study Results of Mazdutide to be Presented at the EASD 2024September 1, 2024 | prnewswire.comInnovent to Present Clinical Data of Multiple Novel Molecules at WCLC and ESMO 2024August 28, 2024 | prnewswire.comInnovent Announces 2024 Interim Results and Business UpdatesAugust 28, 2024 | prnewswire.comChina's First Approved KRAS G12C Inhibitor: Innovent Announces the Approval of Dupert® (Fulzerasib) by the National Medical Products Administration of ChinaAugust 21, 2024 | prnewswire.comInnovent and SanegeneBio Announce First Participant Dosed in a Phase 1 Clinical Trial of IBI3016 (AGT siRNA)August 1, 2024 | prnewswire.comInnovent Announces the NDA of Mazdutide for Type 2 Diabetes has been Accepted by the NMPA of ChinaAugust 1, 2024 | prnewswire.comInnovent and WeComput Announce Strategic Partnership to Advance AI-Driven Drug Discovery and DevelopmentJuly 25, 2024 | prnewswire.comInnovent Biologics : Second Phase 3 Trial Of Mazdutide In Type 2 Diabetes Meets Study EndpointsJuly 22, 2024 | markets.businessinsider.comInnovent Announces the Second Phase 3 Trial of Mazdutide in Chinese Patients with Type 2 Diabetes Met Study Endpoints, and Plans to Submit NDA of Mazdutide to the NMPAJuly 21, 2024 | prnewswire.comInnovent Launches Environmental, Social and Governance (ESG) Website to Advance Sustainability and Corporate ResponsibilityJuly 7, 2024 | prnewswire.comInnovent and IASO Bio Enhance Strategic Collaboration in Cell TherapyJuly 5, 2024 | prnewswire.comInnovent Announces Oral Presentation at the ESMO Gastrointestinal Cancers Congress 2024 on Latest Clinical Data of Anti-CLDN18.2 ADC (IBI343) in Patients with Advanced Gastric/Gastroesophageal Junction AdenocarcinomaJuly 1, 2024 | prnewswire.comInnovent Provides Interpretation and Updates on Clinical Data from Mazdutide GLORY-1 Study and General Biomedicine PipelineJune 27, 2024 | prnewswire.comInnovent Presents the Results of the First Phase 3 Study of Mazdutide for Weight Management at the ADA's 84th Scientific SessionsJune 24, 2024 | prnewswire.comInnovent Announces Mazdutide Demonstrates 80.2% Reduction in Liver Fat Content in Exploratory Analysis of Phase 3 Weight Management GLORY-1 Study at ADA 2024June 24, 2024 | prnewswire.comInnovent Reports Oncology Pipeline Updates at Investor MeetingJune 18, 2024 | prnewswire.comInnovent Delivers Oral Presentation on Clinical Data of IBI363 (First-in-class PD-1/IL-2α-bias Bispecific Antibody Fusion Protein) in Advanced Non-small Cell Lung Cancer and Other Solid Tumors at the 2024 ESMO Virtual PlenaryJune 13, 2024 | prnewswire.comInnovent Receives Fast Track Designation from the U.S. FDA for IBI343 (TOPO1i anti-CLDN18.2 ADC) as Monotherapy for Advanced Pancreatic CancerJune 12, 2024 | prnewswire.comInnovent to Present Multiple Clinical Study Results of Mazdutide at the ADA's 84th Scientific SessionsJune 11, 2024 | prnewswire.comInnovent Delivers Oral Presentation of Clinical Data of A Randomized Controlled Phase 1b Study Evaluating IBI310 (Anti-CTLA-4 Monoclonal Antibody) in Combination with Sintilimab as Neoadjuvant Treatment of Colon Cancer at 2024 ASCO Annual MeetingJune 2, 2024 | prnewswire.comInnovent Delivers Oral Presentations at the 2024 ASCO Annual Meeting on Clinical Data of First-in-Class anti-CLDN18.2/CD3 Bispecific Antibody (IBI389) for the Treatment of Advanced Pancreatic Cancer and Gastric CancerJune 2, 2024 | prnewswire.comInnovent Presents Phase 1 Clinical Data of First-in-class PD-1/IL-2α Bispecific Antibody Fusion Protein (IBI363) in Melanoma, Colorectal Cancer and other Solid Tumors at the 2024 ASCO Annual MeetingJune 1, 2024 | prnewswire.comInnovent Presents at the 2024 ASCO Annual Meeting on Clinical Data of anti-CLDN18.2 ADC (IBI343) in Patients with Advanced Pancreatic Cancer or Biliary Tract CancerJune 1, 2024 | prnewswire.comInnovent:Phase 3 Trial Of Picankibart In Severe Plaque Psoriasis Meets Primary & Key Secondary GoalsMay 28, 2024 | markets.businessinsider.comInnovent Announces Picankibart (IBI112) Achieved Primary Endpoints in a Phase 3 Clinical Trial in Treating Moderate to Severe Plaque Psoriasis, and Plans to Submit NDA to the NMPAMay 27, 2024 | prnewswire.com Get Innovent Biologics News Delivered to You Automatically Sign up to receive the latest news and ratings for IVBXF and its competitors with MarketBeat's FREE daily newsletter. Email Address Trump’s Sending THIS Crypto Higher on Purpose (Ad)Discover the coin set to explode before 2025! Trump could trigger THIS crypto coin… YES, I WANT THE #1 CRYPTO NOW IVBXF Media Mentions By Week IVBXF Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. IVBXF News Sentiment▼1.340.60▲Average Medical News Sentiment IVBXF News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. IVBXF Articles This Week▼11▲IVBXF Articles Average Week Get Innovent Biologics News Delivered to You Automatically Sign up to receive the latest news and ratings for IVBXF and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies AGNPF News Today AKBLF News Today DRTSW News Today ARNI News Today ASPHF News Today ASCLF News Today AVCTF News Today AWKNF News Today AXIM News Today BRRGF News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (OTCMKTS:IVBXF) was last updated on 12/22/2024 by MarketBeat.com Staff From Our PartnersThis Crypto Is Set to Explode in DecemberIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredWARNING: “Buffett Indicator” flashing for first time in 50 yearsWarren Buffett has sold a staggering $97 billion worth of stocks this year... But why? Our research indi...Behind the Markets | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Starting with what I call Exec. Order 001. It’s a bombshell law that I believe Trump will sign within minut...Banyan Hill Publishing | SponsoredYour bank is lying to you.You might think you have your money in a high-yield savings account, but do you really? The national average A...MyBankTracker | SponsoredRare "crisis signal" triggers for third time in U.S. marketA rare pattern has just repeated for the third time in U.S. history. The last two times this happened, the...Stansberry Research | SponsoredAI breakthrough about to upend industryEveryone is talking about AI right now. The talk has been endless ever since ChatGPT was released to the m...Porter & Company | SponsoredCould This Tiny Device Help You Make an Extra $30k a Year?I believe it’s going to power Elon Musk’s next AI revolution… A revolution he believes will be worth more t...Brownstone Research | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Innovent Biologics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Innovent Biologics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
